Stay updated on Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial
Sign up to get notified when there's something new on the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page.

Latest updates to the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange Detected- Revision history updated: v3.5.0 added; v3.4.3 removed.SummaryDifference0.1%

- Check20 days agoChange DetectedA new revision entry v3.4.3 was added to the history and the previous revision v3.4.2 was removed.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedAdded Revision: v3.4.2 to the history and removed the older funding-lapse notice and Revision: v3.4.1; this is an administrative update with no effect on the study data.SummaryDifference0.5%

- Check56 days agoChange DetectedNotice about lapse in government funding added; page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check63 days agoChange DetectedThe history page now includes a glossary toggle, green highlights for additions, red highlights for deletions, and visible revision labels (e.g., Revision: v3.4.0) to improve readability of changes.SummaryDifference0.7%

- Check77 days agoChange DetectedRevision: v3.3.4 updated in the page history (replacing v3.3.3).SummaryDifference0.1%

Stay in the know with updates to Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page.